title: [Interim report of JFMTC study no. 20 on the effectiveness of high dose CDDP plus 5-FU regimen as an adjuvant therapy for far-advanced cancer of the stomach].
abstract: This interim analysis of the JFMTC study as of May, 1998 covers 321 gastrectomized patients with far-advanced stomach cancer from 135 institutions between November, 1993 and March, 1996. The intensive therapy group (I-group) received CDDP i.p. administration on resective surgery with 70 mg/m2 followed by CDDP i.v. of 80 mg/m2 (day 1, i.v.), accompanying 5-FU of 350 mg/m2/day (day 1-5, c.v.i.) in the 4th, 8th and 12th weeks. The I-group was randomly compared with the standard therapy group (S-group) of MMC of 6 mg/m2 i.v. in the 4th, 8th and 12th weeks and UFT of 3-4 capsules daily for postoperative one year. The results obtained were that 1. adverse reactions were found more in the I-group than in the S-group, particularly notable in the decrease in blood cells, loss of appetite and nausea/vomiting, and incidence of grade 3 or more being 13% (neutrophile leukocytes), 26% and 21%, respectively; 2. there was no significant difference between I- and S-groups in terms of 3-year survival or disease-free survival rates. (JFMTC: Japanese Foundation of Multidisciplinary Treatment for Cancer).
authors.affiliation: Dept. of Surgical Oncology, Hiroshima University.
authors.forename: T
authors.initials: T
authors.lastname: Toge
authors.forename: M
authors.initials: M
authors.lastname: Fujita
authors.forename: K
authors.initials: K
authors.lastname: Hirata
authors.forename: Y
authors.initials: Y
authors.lastname: Kunii
authors.forename: M
authors.initials: M
authors.lastname: Kitamura
authors.forename: H
authors.initials: H
authors.lastname: Nagawa
authors.forename: T
authors.initials: T
authors.lastname: Kubota
authors.forename: J
authors.initials: J
authors.lastname: Wakasugi
authors.forename: Y
authors.initials: Y
authors.lastname: Kasai
authors.forename: Y
authors.initials: Y
authors.lastname: Takahashi
authors.forename: H
authors.initials: H
authors.lastname: Furukawa
authors.forename: T
authors.initials: T
authors.lastname: Takao
authors.forename: N
authors.initials: N
authors.lastname: Kaibara
authors.forename: S
authors.initials: S
authors.lastname: Takashima
authors.forename: T
authors.initials: T
authors.lastname: Kakegawa
authors.forename: M
authors.initials: M
authors.lastname: Tomita
authors.forename: Y
authors.initials: Y
authors.lastname: Nose
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D002945:Cisplatin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000401:mortality; D015996:Survival Rate; D005641:Tegafur / Q000008:administration & dosage; D014498:Uracil / Q000008:administration & dosage
chemical_list: D005641:Tegafur; D014498:Uracil; D002945:Cisplatin; D005472:Fluorouracil